PIPELINE

Flexus has advanced into the clinic a dual-inhibitor that targets FLT-3 (including FLT-3 mutations) and CDK4/6 for the treatment of cancer. Our internal research programs are focused on discovering and developing small molecule inhibitors against novel regulatory
T cell targets. We anticipate entering the clinic in 2015 with a selective IDO-1 inhibitor.

Flexus R&D Pipline

1. Worldwide Rights, Flexus Biosciences, Inc. 2. Treg targets not disclosed.

Under the leadership of seasoned R&D executives and the guidance of world-class scientific advisors, Flexus has built an industry-leading internal R&D engine focused on discovering and developing new innovative cancer immunotherapies, with the goal of delivering one IND per year.